Literature DB >> 3519746

The cytoskeleton and extracellular matrix of the Dupuytren's disease "myofibroblast": an immunofluorescence study of a nonmuscle cell type.

J J Tomasek, R J Schultz, C W Episalla, S A Newman.   

Abstract

The cytoskeleton and the extracellular matrix of myofibroblasts in nodules from Dupuytren's diseased palmar fascia were examined by indirect immunofluorescence. Primary antibodies used as probes of these tissue compartments were directed against (1) smooth muscle myosin, (2) nonmuscle myosin--components of the cytoplasmic contractile apparatus in smooth muscle and nonmuscle cells, respectively, (3) laminin, and (4) fibronectin--extracellular glycoproteins mediating cell-matrix attachment in smooth muscle and nonmuscle fibroblastic cells, respectively. The Dupuytren's nodular cells stained for nonmuscle myosin and fibronectin but not for smooth muscle myosin or laminin; this indicated that, at the level of biochemical differentiation, these cells are a nonmuscle type. Staining for fibronectin between nodular cells was dramatically increased over that seen between fibroblasts of the normal palmar fascia. Because of the non-muscle nature of the distinctive contractile cell type of the Dupuytren's nodule, we suggest that the term myofibroblast should be considered a misnomer when applied to this pathogenic cell type.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3519746     DOI: 10.1016/s0363-5023(86)80143-5

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  12 in total

1.  TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin.

Authors:  A Berndt; H Kosmehl; U Mandel; U Gabler; X Luo; D Celeda; L Zardi; D Katenkamp
Journal:  Histochem J       Date:  1995-12

Review 2.  The myofibroblast matrix: implications for tissue repair and fibrosis.

Authors:  Franco Klingberg; Boris Hinz; Eric S White
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

3.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

4.  Evidence for the nonmuscle nature of the "myofibroblast" of granulation tissue and hypertropic scar. An immunofluorescence study.

Authors:  R J Eddy; J A Petro; J J Tomasek
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

5.  WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.

Authors:  Justin Crawford; Christina Raykha; Daevina Charles; Bing Siang Gan; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2015-06-30       Impact factor: 5.782

6.  Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells.

Authors:  Linda Vi; Lucy Feng; Rebecca D Zhu; Yan Wu; Latha Satish; Bing Siang Gan; David B O'Gorman
Journal:  Exp Cell Res       Date:  2009-07-18       Impact factor: 3.905

7.  Myofibroblasts in hollow visceral myopathy: the origin of gastrointestinal fibrosis?

Authors:  J E Martin; M Benson; M Swash; V Salih; A Gray
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

8.  The alpha-smooth muscle actin-positive cells in healing human myocardial scars.

Authors:  I E Willems; M G Havenith; J G De Mey; M J Daemen
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

9.  Smooth muscle and myofibroblast-like cells in the perimedullary stromal basket of kidneys from ringed seals (Phoca hispida).

Authors:  J D Newstead
Journal:  Cell Tissue Res       Date:  1987-11       Impact factor: 5.249

10.  Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-beta2.

Authors:  Raymond Tse; Jeffrey Howard; Yan Wu; Bing Siang Gan
Journal:  BMC Musculoskelet Disord       Date:  2004-11-12       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.